Drugs / JAB-2485
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05490472 | Dec 2022 → Aug 2026 overdue | estrogen-receptor positive breast cancer, small cell lung carcinoma, triple-negative breast carcinoma | Jacobio Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JAB-2485 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05490472 ↗ |
| Action | Inhibit | “Aurora A inhibitor” NCT05490472 ↗ |
| Route | Oral | “Administered orally” NCT05490472 ↗ |